NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
PurposeTo further assess the mid-long term effects of dihydroergotoxine mesylate (DHM) on salivation in patients with Parkinson's disease (PD).MethodsThirty-nine participants were enrolled in a 24-week, open, self-controlled study. After baseline assessments of salivation, swallowing, and motor and cognitive function, the participants were given DHM. The primary outcome was the difference in the Sialorrhea Clinical Scale for Parkinson's disease (SCS-PD) scores of salivation before and after treatment. The secondary outcomes included ≥ 30 % improvement in the SCS-PD score at each posttreatment visit and changes in the scores from other scales.ResultsA total of 39 participants were included in this study, and 4 participants dropped out. Finally, 35 patients completed all the visits. Salivation: After treatment for 1 week, the primary outcome, namely, the median SCS-PD score, decreased from 9.0 (IQR 5.0-12.0) at baseline to 7.0 (IQR 4.7-10.0) (P = 0.03). This effect persisted at 24 weeks, and the median score at 24 weeks was 5.0 (IQR 2.0-8.0) (P ConclusionDHM can significantly ameliorate salivation in PD patients over 24 weeks, with fewer adverse effects.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.